www.pharmatechoutlook.comED I T I O NISSN 2644-2787JUNE - 24 - 2024ImmunotherapyA NOVEL APPROACH IN PRECISION MEDICINEZhi (Zak) L. Chu, Ph.D.,Founder, CEO & CSOCROSSIGNAL Therapeutics, Inc.
Page 2 >